Exscientia | AI Drug Discovery

DARWIN’S TREE.

Tree of knowledge. Tree of life.

Exscientia’s tree sculpture logo is based on a sketch found in Darwin’s notebook where he first proposed a theory of evolution and natural selection. Developing AI to be creative follows similar principles to evolution to generate new ideas and using models to select the best.

Explore

Better drugs faster

Welcome to the world’s leading pharmatech, using AI to precision engineer future drugs for patients and revolutionise drug discovery.

World first

Exscientia are spearheading the drug discovery revolution with the first AI-Designed molecules to reach clinic trials.

Previous Next

Applying AI to drug design is recognised as one of the ultimate scientific challenges

Smarter design decisions with AI

Navigating Chemical Space

Whilst there are trillions of potential molecules, few will ever be made and only a handful fulfill the complex criteria required to warrant testing in the clinic.

Learning efficiently with AI

Drug discovery is best thought of as a learning problem. Faster learning identifies compounds that fit a project’s clinical brief more rapidly and efficiently.

Exscientia AI

Exscientia AI systems are better at learning than traditional human-led design allowing molecules to reach the clinic faster.

Smarter design decisions with AI

Navigating Chemical Space

Whilst there are trillions of potential molecules, few will ever be made and only a handful fulfill the complex criteria required to warrant testing in the clinic.

Learning efficiently with AI

Drug discovery is best thought of as a learning problem. Faster learning identifies compounds that fit a project’s clinical brief more rapidly and efficiently.

Exscientia AI

Exscientia AI systems are better at learning than traditional human-led design allowing molecules to reach the clinic faster.

Previous Next

Revolutionising drug discovery

The pharmaceutical industry has only recently acknowledged the potential of AI. Projects still routinely require 2000-3000 molecules to be made over many years before a single compound suitable for clinical testing is trialed.

Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.

Faster by design

At Exscientia we put AI algorithms at the heart of design and data interpretation.

Better by design

Our AI systems optimise properties in parallel rather than sequentially.

Better by design

Using AI to design and optimise molecular properties in parallel, rather than sequentially, increases the likelihood of discovering a candidate with exquisitely balanced pharmacology that will deliver therapeutic benefit in the clinic.

Faster by design

By putting AI at the heart of design as well as data interpretation, we put faith in its ability to rapidly identify optimal drug discovery paths. Through more efficient learning the systems determine the next step faster than incumbent methods.

Precision design

The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.

Revolutionising drug discovery

Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.

Faster by design

At Exscientia we put AI algorithms at the heart of design and data interpretation.

Better by design

Our AI systems optimise properties in parallel rather than sequentially.

Better by design

Faster by design

Precision design

The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.

Revolutionising drug discovery

Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.

Faster by design

At Exscientia we put AI algorithms at the heart of design and data interpretation.

Better by design

Our AI systems optimise properties in parallel rather than sequentially.

Better by design

Faster by design

Precision design

The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.

Previous Next

Drug discovery is a
learning challenge

Faster learning shortens discovery times and improves outcomes. AI is simply better at learning from complex data sets than humans and better at determining what to do next. We demonstrated this with our ‘Human vs Machine’ data, published in Nature. The results were clear.

Discover more

Patient First AI

Our mission is to design and develop novel, precision engineered drugs with an improved probability of clinical success for the benefit of patients.

Together we make unparalleled progress

Learn more

Careers at Exscientia

Join us on our mission

We are a creative, passionate and collaborative organisation dedicated to setting bold new standards in drug discovery and design. If you have the ingenuity, energy and ambition to help us change the world, we would love to hear from you.

Open positions

Better drugs faster

World first

Exscientia are spearheading the drug discovery revolution with the first AI-Designed molecules to reach clinic trials.

Applying AI to drug design is recognised as one of the ultimate scientific challenges

Revolutionising drug discovery

Faster by design

Better by design

Revolutionising drug discovery

Faster by design

Better by design

Drug discovery is a learning challenge

Patient First AI

Careers at Exscientia

Drug discovery is a
learning challenge